B.Sc Grad. Dip. App. Soc. Psych
Geoffrey Kempler was appointed Chairman and Non-executive Director of Optheain December 2015. He has extensive experience in the global biopharmaceutical industry having led Prana Biotechnology, a company he founded, for over 20 years.
His investment markets experience includes a strong domestic and international network of specialist and sophisticated investors. He was responsible for the listing of Prana Biotechnology on both the ASX and NASDAQ and has raised approximately $150 million in capital via traditional equity transactions and value accretive alternative financing models.
He founded Prana in 1997 and has been responsible for setting the operational and commercial objectives including multiple global patient trials. Geoffrey is a qualified psychologist and holds a B.Sc degree in science from Monash University and Grad. Dip. App. Soc. Psych. degree from Swinburne University.
Chief Executive Officer (CEO) & Managing Director
Dr Megan Baldwin was appointed CEO and Managing Director in February 2014. Dr Baldwin brings over 20 years of experience focussing on angiogenesis and therapeutic strategies for cancer and ophthalmic indications.
Dr Baldwin joined Opthea in 2008 and since then has held various positions, including Head of preclinical R&D and Chief executive officer Opthea Pty Ltd, the 100% owned subsidiary of Opthea, developing OPT-302 for the treatment of wet age-related macular degeneration. prior to joining Opthea, she was employed at Genentech (now Roche), the world leader in the field of angiogenesis-based therapies for cancer and other diseases.
Her experience included several years as a researcher in the group of leading angiogenesis expert Napoleone Ferrara, before moving to Genentech’s commercial division and having responsibility for corporate competitive intelligence activities. In these roles, she developed extensive commercial and scientific knowledge in the field of anti-angiogenic and oncology drug development.
She holds a PhD in Medicine from the University of Melbourne, having conducted her doctoral studies at the Ludwig Institute for Cancer Research on the biology of VEGF-C and VEGF-D, is a member of the Australian Institute of Company Directors and a director of Ausbiotech.
Michael Sistenich was appointed non-executive director of Opthea in November 2015 and is Chairman of the remuneration and audit committees.
Michael Sistenich has advised a wide range of global institutions, high net worth individuals and companies on healthcare investments over the past 20 years. He is a healthcare specialist in international investment management and investment banking, and led the Bell Potter team which advised the Company through the $17.4M capital raising in November 2014.
Michael Sistenich is currently a director of Nohla therapeutics, and previously served as director of International Equities and Head of Global Healthcare Investments at DWS Investments, Deutsche Bank Frankfurt. Michael has long standing capital market connections and experience in the global healthcare investment community.